Indian Council of Agricultural Research
CENTRAL MARINE FISHERIES RESEARCH INSTITUTE

HomeLATEST NEWS

CMFRI commercialized Nutraceuticals for use against arthritis, type-2 diabetes and hypertension

ICAR-CMFRI commercialized Nutraceuticals for use against arthritis, type-2 diabetes and hypertension to Pioneer Pharmaceuticals Limited-a leading wellness and Pharmaceutical Company based at Kochi

CadalminTM Green Algal extract (CadalminTM GAe), Antidiabetic extract (CadalminTM ADe), and Antihypertensive extract (CadalminTM AHe), three patent-protected nutraceutical products developed by ICAR-Central Marine Fisheries Research Institute, as natural remedies for joint pain/arthritis, type-2 diabetes and hypertensive disorders from seaweeds, were commercialized with Pioneer Pharmaceuticals Limited-a leading wellness and pharmaceutical company based at Kochi. Seaweeds are the natural bounty of the Sea, and are known for their extraordinary medicinal properties. 

Dr. A. Gopalakrishnan, Director, ICAR-CMFRI signed an exclusive license agreement with Mrs. Nancy Joby (Managing Partner), along with Mr. Joby George, Joel Joby George, Mathews Simon and B.C Kumar on 9th September for their commercial production and marketing.


Nutraceuticals for use against arthritis, type-2 diabetes and hypertension


Seaweeds are commonly available in the Indian coastal waters, and are gaining immense attention in nutraceutical industries due to their protective function against various chronic diseases


Bioactive principles in CadalminTM GAe competitively inhibit pro-inflammatory cyclooxygenase-2 and lipooxygenase, resulting in decreased production of inflammatory prostaglandins and leukotrienes, thereby hindering the occurrence of inflammatory pain and arthritis. Bioactive pharmacophore leads from seaweeds were used to develop CadalminTM AHe, which can be administered to regulate clinical indicators leading to pathophysiology leading to hypertension that is one of the risk factors for strokes, heart attacks, heart failure, and arterial aneurysm, and is a leading cause of chronic kidney failure. The bioactive ingredients in CadalminTM AHe blocks angiotensin converting enzyme that converts angiotensin I to angiotensin II.  Decreased production of angiotensin II enhances natriuresis, lowers blood pressure, and prevents remodeling of smooth muscle and cardiac myocytes. The bioactive ingredients in CadalminTM AHe also effectively modulate the serum level of oxidative stress marker nitric oxide, lipid peroxidase and the potent vasoconstrictor angiotensin-II.

CadalminTM ADe, an anti-diabetic nutraceutical to combat type-2 diabetes, contains 100% natural marine bioactive ingredients extracted from seaweeds by a patented technology. The bioactive ingredients in CadalminTMADe competitively inhibit dipeptidyl peptidase-IV and tyrosine phosphatase 1B, thereby hindering the occurrence of type-2 diabetes. The active ingredients interfere with the release of simple sugars from the gut, which in turn reduces postprandial (after eating) hyperglycemia (high blood sugar levels). 

These nutraceutical products contain 100% natural marine bioactive ingredients from selected seaweeds by patented technologies, and would be made available in 400 mg plant-based capsules to meet the dietary needs of the large vegetarian population in India and abroad, by Pioneer Pharmaceuticals Limited. Preclinical trials showed no side-effects and toxicity related significant changes in the mammalian subjects. 

These nutraceutical products were prepared from seaweeds, which are commonly available in the Indian coastal waters. The ICAR-CMFRI is in the process of developing more health products from seaweeds towards their utilization based on the National Policy to harness the potential of this natural wealth of Indian coastal waters. 

Seaweeds are commonly available in the Indian coastal waters, and are gaining immense attention in nutraceutical industries due to their protective function against various chronic diseases. Indian nutraceuticals market has been growing at the compound annual growth rate of 20 per cent for the past three years, particularly in the segments of functional food. These developments point towards the fast proliferation of the specific segments of nutraceuticals in India and its acceptance by the Indian consumers and healthcare providers. 

These products will be manufactured and marketed by Pioneer Pharmaceuticals Limited, Kochi.

CMFRI adjudged as best research institute under ICAR

CMFRI adjudged as best research institute under ICAR

CMFRI wins ICAR’s highest award

The Central Marine Fisheries Research Institute (CMFRI) has been adjudged as the best research institute of the Indian Council of Agricultural Research (ICAR). The CMFRI won the Sardar Patel Outstanding ICAR institutions award, the highest award of the ICAR in the category of the large institutions with a cash prize of Rs 10 Lakhs, a Silver Plaque, Certificate and Citation.This is in recognition of CMFRI’s excellent performance in marine fisheries research during the period from 2014 to 2019.

Certificate

This is the second time CMFRI bagging this prestigious award. Various cutting edge research activities including development of mariculture technologies such as open sea cage fish farming, seaweed farming, integrated multi-trophic aquaculture (IMTA) and breeding and seed production technologies for marine food fish and ornamental fishes which were aimed to enhance the income of fishermen helped CMFRI achieving the highest ranking among more than 110 agricultural and allied research institutes in the country. CMFRI’s efforts on preparing a range of policy guidelines, including the works on minimum legal size (MLS), National Policy on Mariculture and ecosystem-based management towards the sustainable utilization of marine fisheries resources were well appreciated. Its research initiatives in developing nutraceutical products from marine organisms to treat type 2 diabetes, arthritis, obesity, thyroid and hypertension also played a major role in winning the award. In addition, the institute exhibited leadership in winning several externally funded research projects such as National Brood bank for Cobia and Silver pompano and a Centre of Excellence and Innovation  funded by the DBT. The institute also obtained many patents during the period.


Citation